« Back
Home /
Ivacaftor-d9

Ivacaftor-d9

Item no.	HY-13017S-10mg
Manufacturer	MedChem Express
CASRN	1413431-07-8
Amount	10 mg
Quantity options	10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.83
Citations	[1]Scott L Harbeson, et al. Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development. J Pharmacol Exp Ther. 2017 Aug;362(2):359-367.
Smiles	CC(C)(C1=CC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=C(C=C1NC(C2=CNC(C=CC=C3)=C3C2=O)=O)O)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	VX-770-d9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Isotope-Labeled Compounds
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	CFTR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	401.55
Product Description	Ivacaftor-d9 is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50mg/mL (ultrasonic)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13017S-10mg-safety-datasheet.pdf